TDMS Study 05203-09 Pathology Tables
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
MICE/FINAL#1
Facility: Southern Research Institute
Chemical CAS #: 88-72-2
Lock Date: 03/08/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 4 6 7 22
Natural Death 4 8 6 33
Survivors
Terminal Sacrifice 52 46 47 5
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (59) (57)
Gallbladder (54) (53) (54) (31)
Intestine Large, Colon (56) (55) (57) (41)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Intestine Large, Cecum (56) (53) (54) (32)
Carcinoma 1 (2%) 4 (7%) 3 (9%)
Sarcoma 1 (2%)
Intestine Small, Jejunum (56) (53) (56) (34)
Carcinoma 1 (3%)
Intestine Small, Ileum (57) (53) (56) (34)
Liver (60) (59) (59) (60)
Cholangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 2 (3%) 3 (5%) 4 (7%) 9 (15%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (3%) 7 (12%)
Hepatocellular Adenoma 7 (12%) 5 (8%) 16 (27%) 9 (15%)
Hepatocellular Adenoma, Multiple 3 (5%) 20 (33%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (11) (9) (9) (34)
Carcinoma, Metastatic, Uncertain Primary Site 1 (11%)
Carcinoma, Metastatic, Intestine Large, Cecum 1 (11%)
Hemangiosarcoma 25 (74%)
Hemangiosarcoma, Multiple 7 (21%)
Histiocytic Sarcoma 1 (11%)
Sarcoma 1 (3%)
Page 2
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Multiple 1 (11%)
Sarcoma, Metastatic, Skin 1 (11%)
Sarcoma, Metastatic, Skeletal Muscle 1 (11%)
Pancreas (60) (57) (58) (57)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Salivary Glands (59) (59) (58) (49)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (60) (58) (58) (59)
Hemangioma 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (3%) 2 (3%) 1 (2%)
Stomach, Glandular (58) (57) (57) (52)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (59) (58)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (59) (58) (60)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (59) (57) (58) (59)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (60) (57) (60) (56)
Carcinoma 1 (2%)
Pituitary Gland (58) (58) (53) (53)
Adenoma 1 (2%)
Pars Distalis, Adenoma 2 (3%) 4 (7%) 3 (6%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (60) (59) (58) (53)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (3) (3)
Abdominal, Hemangiosarcoma 1 (33%)
Abdominal, Hemangiosarcoma, Multiple 1 (33%)
Thoracic, Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (56) (56) (56)
Carcinoma 1 (2%)
Cystadenoma 1 (2%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 2 (3%) 1 (2%) 1 (2%)
Teratoma Malignant 1 (2%)
Tubulostromal Adenoma 1 (2%)
Oviduct (1)
Uterus (60) (59) (60) (59)
Hemangioma 1 (2%) 2 (3%)
Hemangiosarcoma 1 (2%) 2 (3%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Cervix, Hemangiosarcoma 1 (2%)
Endometrium, Carcinoma 1 (2%)
Endometrium, Polyp Stromal 2 (3%) 2 (3%) 2 (3%)
Vagina (1)
Carcinoma, Metastatic, Uncertain Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (58) (60) (60)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (6) (3) (10) (11)
Iliac, Sarcoma, Metastatic, Skin 1 (9%)
Inguinal, Sarcoma, Metastatic, Skin 1 (10%)
Mediastinal, Sarcoma, Metastatic, Uncertain
Primary Site 1 (9%)
Pancreatic, Sarcoma 1 (10%)
Renal, Hemangiosarcoma, Metastatic, Mesentery 1 (9%)
Page 4
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Renal, Sarcoma, Metastatic, Skin 1 (10%) 1 (9%)
Lymph Node, Mandibular (58) (55) (55) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (53) (58) (57) (57)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Spleen (59) (57) (58) (57)
Histiocytic Sarcoma 1 (2%)
Thymus (57) (56) (55) (44)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Basal Cell Carcinoma 1 (2%)
Basosquamous Tumor Malignant 1 (2%)
Subcutaneous Tissue, Carcinoma, Multiple 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (3%) 16 (27%)
Subcutaneous Tissue, Hemangiosarcoma,
Multiple 3 (5%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 5 (8%) 2 (3%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteosarcoma 1 (2%)
Femur, Osteosarcoma 1 (2%)
Skeletal Muscle (2) (3) (3) (18)
Carcinoma, Metastatic, Uncertain Primary Site 1 (33%)
Hemangioma 1 (50%)
Hemangiosarcoma 14 (78%)
Hemangiosarcoma, Multiple 2 (11%)
Sarcoma 1 (33%) 2 (67%) 1 (6%)
Sarcoma, Multiple 1 (33%) 1 (6%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (59) (57)
Alveolar/Bronchiolar Adenoma 2 (3%) 3 (5%) 4 (7%) 4 (7%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%) 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Carcinoma 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Harderian Gland 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Mediastinum, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skeletal
Muscle 1 (2%)
Nose (60) (60) (59) (57)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (1) (4) (4)
Adenoma 4 (80%) 1 (25%) 2 (50%)
Carcinoma 1 (20%) 1 (100%) 3 (75%) 2 (50%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (56) (58) (59)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (59) (54) (57) (54)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Lymphoma Malignant 8 (13%) 7 (12%) 5 (8%) 3 (5%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 33 37 44 56
Total Primary Neoplasms 42 51 76 146
Total Animals with Benign Neoplasms 21 20 26 33
Total Benign Neoplasms 26 22 35 38
Total Animals with Malignant Neoplasms 16 23 27 55
Total Malignant Neoplasms 16 29 41 108
Total Animals with Metastatic Neoplasms 4 6 12
Total Metastatic Neoplasm 12 11 16
Total Animals with Malignant Neoplasms 1 1 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Natural Death 5 21 39 29
Moribund Sacrifice 3 5 21 31
Survivors
Terminal Sacrifice 52 34
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (54) (42) (31) (35)
Intestine Large, Colon (56) (52) (46) (54)
Muscularis, Serosa, Hemangiosarcoma 1 (2%)
Intestine Large, Cecum (56) (49) (36) (44)
Carcinoma 12 (24%) 9 (25%)
Intestine Small, Duodenum (55) (45) (40) (42)
Hemangiosarcoma 1 (2%)
Intestine Small, Jejunum (56) (43) (35) (40)
Adenocarcinoma 1 (2%)
Carcinoma 1 (2%)
Intestine Small, Ileum (55) (40) (35) (39)
Carcinoma 1 (3%)
Liver (60) (59) (57) (60)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 3 (5%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 9 (15%) 9 (15%) 4 (7%) 2 (3%)
Hepatocellular Carcinoma, Multiple 3 (5%) 7 (12%) 1 (2%)
Hepatocellular Adenoma 15 (25%) 12 (20%) 1 (2%)
Hepatocellular Adenoma, Multiple 3 (5%) 6 (10%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mesentery (12) (12) (42) (38)
Carcinoma, Metastatic, Intestine Large, Cecum 1 (8%) 1 (2%)
Hemangiosarcoma 8 (67%) 30 (71%) 24 (63%)
Hemangiosarcoma, Multiple 8 (19%) 14 (37%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Page 9
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pancreas (59) (59) (59) (58)
Hemangiosarcoma 1 (2%)
Acinus, Hemangiosarcoma 1 (2%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (58) (60)
Squamous Cell Papilloma 2 (3%)
Stomach, Glandular (57) (54) (53) (55)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Hemangiosarcoma 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (58) (60)
Adenoma 1 (2%)
Capsule, Adenoma 1 (2%)
Pituitary Gland (53) (50) (50) (46)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (59) (59) (59) (59)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (2) (3)
Hemangiosarcoma 1 (33%)
Pelvic, Hemangiosarcoma 1 (50%) 1 (33%)
Thoracic, Sarcoma 1 (50%)
Thoracic, Sarcoma, Multiple 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (2) (1)
Hemangiosarcoma 1 (50%)
Preputial Gland (60) (59) (59) (60)
Histiocytic Sarcoma 1 (2%)
Prostate (60) (59) (57) (58)
Page 10
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangiosarcoma 4 (7%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Testes (60) (60) (60) (60)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (3) (4) (7) (1)
Inguinal, Hemangiosarcoma, Metastatic,
Skeletal Muscle 1 (100%)
Mediastinal, Hemangiosarcoma, Metastatic,
Mesentery 1 (14%)
Mediastinal, Sarcoma, Metastatic, Tissue NOS 1 (33%)
Pancreatic, Histiocytic Sarcoma 1 (25%)
Lymph Node, Mandibular (59) (55) (50) (54)
Hemangioma 1 (2%)
Lymph Node, Mesenteric (60) (55) (56) (53)
Carcinoma, Metastatic, Intestine Large, Cecum 1 (2%) 3 (5%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (60) (60) (58) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (3%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
Thymus (57) (52) (45) (54)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Sebaceous Gland, Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 4 (7%) 8 (13%) 12 (20%)
Subcutaneous Tissue, Hemangiosarcoma,
Multiple 8 (13%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Cranium, Osteoma 1 (2%)
Skeletal Muscle (1) (6) (35) (47)
Hemangiosarcoma 6 (100%) 25 (71%) 19 (40%)
Hemangiosarcoma, Multiple 8 (23%) 26 (55%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 9 (15%) 6 (10%) 4 (7%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 1 (2%) 2 (3%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%)
Carcinoma, Metastatic, Intestine Large, Cecum 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 3 (5%) 1 (2%)
Hemangiosarcoma, Metastatic, Skin 3 (5%) 4 (7%)
Hemangiosarcoma, Metastatic, Uncertain
Primary Site 1 (2%) 1 (2%) 2 (3%)
Hemangiosarcoma, Metastatic, Skeletal Muscle 2 (3%) 8 (13%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Hemangiosarcoma 4 (7%)
Nose (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
External Ear, Neural Crest Tumor, Malignant 1 (100%)
Harderian Gland (5) (3) (3)
Adenoma 4 (80%) 1 (33%) 1 (33%)
Carcinoma 1 (20%) 1 (33%) 1 (33%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (58) (59) (58) (60)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Hemangiosarcoma 1 (2%)
Urinary Bladder (59) (59) (59) (60)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 3 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 05203-09 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-NITROTOLUENE Date: 11/30/00
Route: DOSED FEED Time: 09:09:35
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 1250 PPM 2500 PPM 5000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 50 59 60
Total Primary Neoplasms 69 92 117 117
Total Animals with Benign Neoplasms 30 24 8 2
Total Benign Neoplasms 36 28 9 2
Total Animals with Malignant Neoplasms 26 41 59 60
Total Malignant Neoplasms 33 64 108 115
Total Animals with Metastatic Neoplasms 1 5 13 17
Total Metastatic Neoplasm 2 6 18 17
Total Animals with Malignant Neoplasms 1 1 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------